Tarsus Pharmaceuticals annual return on equity
2020
2021
2022
2023
2024
2025
Tarsus Pharmaceuticals Return on Equity (ROE) Growth & History (TARS)
Tarsus Pharmaceuticals's return on equity was −23.39% for fiscal 2025.
View full Tarsus Pharmaceuticals company overviewTarsus Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −23.39% | +31.44 pp |
| 2024 | 2024-12-31 | −54.83% | +14.88 pp |
| 2023 | 2023-12-31 | −69.71% | −35.18 pp |
| 2022 | 2022-12-31 | −34.53% | −26.22 pp |
| 2021 | 2021-12-31 | −8.31% | +25.21 pp |
| 2020 | 2020-12-31 | −33.52% | — |
Tarsus Pharmaceuticals quarterly return on equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −5.33% | +0.69 pp |
| Q1 2026 | 2026-03-31 | −2.01% | +6.85 pp |
| Q4 2025 | 2025-12-31 | −2.47% | +7.54 pp |
| Q3 2025 | 2025-09-30 | −3.77% | +5.79 pp |
| Q2 2025 | 2025-06-30 | −6.03% | +6.60 pp |
| Q1 2025 | 2025-03-31 | −8.86% | +6.27 pp |
| Q4 2024 | 2024-12-31 | −10.01% | +10.40 pp |
| Q3 2024 | 2024-09-30 | −9.56% | +12.10 pp |
| Q2 2024 | 2024-06-30 | −12.62% | +6.95 pp |
| Q1 2024 | 2024-03-31 | −15.13% | −2.35 pp |
| Q4 2023 | 2023-12-31 | −20.41% | −13.53 pp |
| Q3 2023 | 2023-09-30 | −21.67% | −11.05 pp |
| Q2 2023 | 2023-06-30 | −19.57% | −16.47 pp |
| Q1 2023 | 2023-03-31 | −12.79% | +0.03 pp |
| Q4 2022 | 2022-12-31 | −6.88% | +1.71 pp |
| Q3 2022 | 2022-09-30 | −10.62% | −2.17 pp |
| Q2 2022 | 2022-06-30 | −3.10% | −6.48 pp |
| Q1 2022 | 2022-03-31 | −12.81% | −18.75 pp |
| Q4 2021 | 2021-12-31 | −8.59% | +6.89 pp |
| Q3 2021 | 2021-09-30 | −8.45% | — |
| Q2 2021 | 2021-06-30 | 3.38% | — |
| Q1 2021 | 2021-03-31 | 5.94% | — |
| Q4 2020 | 2020-12-31 | −15.48% | — |
Tarsus Pharmaceuticals return on equity trends
Over the last five fiscal years, Tarsus Pharmaceuticals's return on equity increased from −33.52% to −23.39%, a change of +10.13 percentage points. The latest reported quarter, Q2 2026, shows −5.33%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tarsus Pharmaceuticals source filings ↗